Edition:
United States

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

7.05USD
13 Dec 2017
Change (% chg)

$-0.05 (-0.70%)
Prev Close
$7.10
Open
$7.15
Day's High
$7.35
Day's Low
$6.80
Volume
30,535
Avg. Vol
20,242
52-wk High
$11.73
52-wk Low
$5.60

Chart for

About

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio... (more)

Overall

Beta: --
Market Cap(Mil.): $123.10
Shares Outstanding(Mil.): 16.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Cidara Therapeutics Completes Enrollment in Phase 2 Strive Trial for Antifungal Rezafungin

* CIDARA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 STRIVE TRIAL EVALUATING NOVEL ANTIFUNGAL REZAFUNGIN (CD101 IV) IN INVASIVE FUNGAL INFECTIONS Source text for Eikon: Further company coverage:

Nov 28 2017

BRIEF-Cidara Therapeutics announces pricing of $20 mln private placement

* Cidara Therapeutics announces pricing of $20 million private placement of common stock

Oct 19 2017

BRIEF-Cidara Q2 net loss per share $0.99​

* Cidara provides corporate update and reports second quarter 2017 financial results

Aug 09 2017

BRIEF-Cidara Therapeutics updates on results from studies investigating antifungal CD101

* Cidara therapeutics inc - ‍announces publication of results from in vivo study investigating novel antifungal CD101 in intra-abdominal candidiasis (IAC)​

Aug 01 2017

BRIEF-Broadfin Capital reports 5.28 percent passive stake in Cidara Therapeutics as of July 7

* Broadfin Capital LLC reports a 5.28 percent passive stake in Cidara Therapeutics Inc as of July 7, 2017 - SEC filing Source text for Eikon: Further company coverage:

Jul 13 2017

BRIEF-Prosight Management LP reports 5.2 pct passive stake in Cidara Therapeutics - SEC filing

* Prosight Management LP reports a 5.2 percent passive stake in Cidara Therapeutics Inc as of June 7, 2017 - SEC filing Source text - (http://bit.ly/2rEN8RH) Further company coverage:

Jun 16 2017

Earnings vs. Estimates